About me

Dr. Stefanie M. Ueda is a surgeon who specializes in gynecologic cancers. She has particular interests in ovarian cancer and robotic surgery.

Ueda's research has addressed conditions including low-grade serous and clear cell ovarian cancers, and uterine serous cancer. She has also studied biologically targeted therapies and treatment outcomes.

Ueda earned her medical degree with honors from New York University School of Medicine. She completed a residency in obstetrics and gynecology at the University of Hawai'i, followed by a fellowship at the Johns Hopkins Kelly Gynecologic Oncology Service.

Ueda has received awards for cancer research from the HERA Women's Cancer Foundation and Entertainment Industry Foundation. She is a member of the Society of Gynecologic Oncology.

  • Education

    New York University School of Medicine, 2002

  • Residencies

    University of Hawai'i Hospital, Obstetrics & Gynecology, 2006

  • Fellowships

    John Hopkins Hospital, Gynecological Oncology

  • Academic Title

    Associate Professor

Gynecologic Surgical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

My reviews

4.7

Overall Experience
210 Reviews
Dr Ueda is a highly intelligent excellent physician. She has taken my situation seriously and is very active in helping me pursue appropriate treatment options. I am indebted to her for her care and concern and her surgical skill.
Explained things in a way that was easy to understand
210 Reviews
Did the doctor pay attention to your concerns
210 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
202 Reviews
Knew the important information about your medical history
208 Reviews
The provider showed respect for what you had to say
209 Reviews
The provider spent enough time with me
207 Reviews

Selected research

Decorative Caduceus

Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cerv...

To assess the Objective Response Rate (ORR) to the treatment of AGEN2034 (anti-PD-1) administered with placebo (Treatment Arm 1 - monotherapy), or with AGEN1884 (anti-CTLA4) (Treatment Arm 2 - combination therapy), defined as the ...

Recruiting

Share